Health News | Study Reveals Fecal Transplant as Promising Treatment for Non-alcoholic Fatty Liver Disease
Get latest articles and stories on Health at LatestLY. Washington D.C. A team of researchers found fecal transplants or stool transplant as a promising treatment for non-alcoholic fatty liver disease (NAFLD).
Washington D.C. [USA], June 14 (ANI): A team of researchers found fecal transplants or stool transplant as a promising treatment for non-alcoholic fatty liver disease (NAFLD).
The research study comes from Lawson Health Research Institute and Western University and has been published in the American Journal of Gastroenterology.
It found that fecal transplants in patients with NAFLD result in a reduction in how easily pathogens and other unwanted molecules pass through the human gut and into circulation, known as intestinal permeability. The results could have implications for the treatment of numerous conditions including metabolic syndrome and autoimmune diseases.
"Intestinal permeability plays a role in the development of metabolic syndrome which is a major cause of coronary and cerebrovascular disease. It has also been associated with autoimmune diseases like multiple sclerosis (MS), rheumatoid arthritis, systemic lupus, and type 1 diabetes," explained Dr. Michael Silverman, Associate Scientist at Lawson and Professor at Western's Schulich School of Medicine & Dentistry.
Also Read | Coronavirus Vaccine: AstraZeneca Awarded Deal to Supply Europe With 400 Million Doses by 2020-End.
Many NAFLD patients have increased intestinal permeability which triggers inflammation, increased fat in the liver, insulin resistance, and elevated levels of triglycerides in the blood. The human microbiome - the diverse collection of microbes in our body - is thought to play a role. Previous studies have shown differences between the gut microbiome of NAFLD patients compared to healthy individuals.
"Our team wondered whether we could change the gut microbiome of NAFLD patients to reduce intestinal permeability," said Dr. Jeremy Burton, Lawson Scientist and Associate Professor at Schulich Medicine & Dentistry.The trial included 21 NAFLD patients from the London Health Sciences Centre (LHSC) and St. Joseph's Health Care London.Patients were randomized to receive a fecal transplant using stool from a healthy donor or a placebo (the patient's own stool). Fecal material was delivered to the small intestine using endoscopy. Patients were followed for six months to assess changes to their gut microbiome, intestinal permeability, percentage of liver fat, and insulin resistance.
While the researchers found no changes in the percentage of liver fat or insulin resistance, they observed a significant reduction in intestinal permeability in those patients who had elevated intestinal permeability at the study's start (seven patients in total). They also observed changes to the gut microbiome in all patients who received a fecal transplant from a healthy donor.
"Our study demonstrates that intestinal permeability can be improved through fecal transplant from a healthy donor," said Dr. Laura Craven, a recent PhD graduate from Schulich Medicine & Dentistry and first author on the published study.
"This suggests that fecal transplant could be used as an early intervention in the treatment of NAFLD to reduce intestinal permeability and prevent inflammation," Craven added.
"Our findings have implications for other conditions too. Changing the gut microbiome could hold promise in preventing and treating metabolic syndrome and autoimmune diseases associated with increased gut permeability," said Dr. Silverman, who is also Chair/Chief of Infectious Diseases at Western, LHSC and St. Joseph's. (ANI)
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)